Attached files

file filename
EX-32 - Emergent BioSolutions Inc.exhibit32_2.htm
EX-32 - Emergent BioSolutions Inc.exhibit32_1.htm
EX-31 - Emergent BioSolutions Inc.exhibit31_2.htm
EX-31 - Emergent BioSolutions Inc.exhibit31_1.htm
EX-10.5 - Emergent BioSolutions Inc.exhibit10_5.htm
EX-10.4 - Emergent BioSolutions Inc.exhitbit10_4.htm
EX-10.3 - Emergent BioSolutions Inc.exhibit10_3.htm
EX-10.2 - Emergent BioSolutions Inc.exhibit10_2.htm
10-Q - Emergent BioSolutions Inc.form10-q032018.htm
 EXHIBIT 12
 
   
Ratio of Earnings to Fixed Charges        
   
Year to Date
                   
 
 
June 30,
   
Year Ended December 31,     
(in thousands)
 
2018
   
2017
   
2016
   
2015
   
2014
   
2013
 
                     
Pretax income from continuing operations (1)
 
$
56,398
 
 
$
118,633
   
$
99,221
   
$
135,716
   
$
84,194
   
$
83,439
                                               
Fixed charges
                                             
    Interest expense
   
1,200
     
6,987
     
8,270
     
7,834
     
7,480
     
1,973
    Debt issuance cost
   
190
     
1,759
     
1,526
     
1,564
     
3,290
     
319
Total fixed charges (2)
   
1,390
     
8,746
     
9,796
     
9,398
     
10,770
     
2,292
                                               
Noncontrolling interest in pretax income (3)
   
-
     
-
     
-
     
-
     
-
     
876
Capitalized interest (4)
   
148
     
2,156
     
2,179
     
2,875
     
2,530
     
1,973
                                               
Earnings ((1) + (2) -(3) -(4))
   
57,640
 
   
125,223
     
106,838
     
142,239
     
92,434
     
82,882
Fixed charges
   
1,390
     
8,746
     
9,796
     
9,398
     
10,770
     
2,292
                                               
Ratio of earnings to fixed charges
   
41.5
     
14.3
     
10.9
     
15.1
     
8.6
     
36.2